1,500
Participants
Start Date
January 20, 2015
Primary Completion Date
June 1, 2016
Study Completion Date
November 1, 2020
VSVG-ZEBOV
The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)
ChAd3-EBO Z
The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.
Placebo
Liberian Ministry of Health and Social Welfare, Monrovia
National Institute of Allergy and Infectious Diseases (NIAID)
NIH